|By Business Wire||
|June 26, 2014 06:06 AM EDT||
Precision Therapeutics, Inc. announces that two key manuscripts on the ChemoFx® drug response marker have been accepted for publication. British Journal of Cancer, the elite professional medical journal of Cancer Research UK, has accepted a manuscript detailing the predictive abilities of ChemoFx. In addition, Clinical and Translational Oncology has accepted a manuscript that examines whether access to ChemoFx results has a positive impact on patient outcomes. Together, these key publications will provide further evidence of the clinical utility of the drug response marker as well as answer important clinical questions asked by physicians personalizing patient treatment and payers covering this important test.
The first manuscript, Evaluation of a Chemoresponse Assay as a Predictive Marker in the Treatment of Recurrent Ovarian Cancer: Further Analysis of a Prospective Study, utilizes four separate statistical analyses to examine whether ChemoFx is able to identify specific sensitive treatments for ovarian cancer patients. The identified chemotherapies could potentially be more effective for the individual patient. Initial findings were presented at the 2013 European Cancer Congress Annual Meeting.
The second manuscript, Overview of a Chemoresponse Assay in Ovarian Cancer, is the full publication of an abstract presented at the 2013 AACR Meeting - Advances in Ovarian Cancer Research: From Concept to Clinic. This manuscript releases a comparative analysis conducted between a Herzog, 2010 study and four previously accrued and published National Cancer Institute (NCI) funded cooperative group drug studies in advanced epithelial ovarian cancer. The publication examines whether patients treated by physicians with access to assay results experience improved outcomes when compared to patients treated by physicians without access to ChemoFx results.
“The implications of these findings are pivotal to the gynecologic cancer community, particularly for women at high risk, for survivors fighting the disease and for those facing recurrence,” said Arlette H. Uihlein, MD, Medical Director of Precision Therapeutics. “A study showing that ChemoFx can not only predict how a patient will respond to treatment, but also to which treatment that patient will benefit, has the potential to change treatment paradigms.”
ChemoFx is a proprietary drug response marker which quantifies an individual gynecologic cancer patient’s probable tumor response to a range of standard chemotherapeutic options. ChemoFx has been validated in previously conducted clinical studies, with data demonstrating a 14-month improvement in overall survival and 50% increase in progression-free survival when recurrent ovarian cancer patients are treated with ‘responsive’ therapies as indicated by ChemoFx.
About Ovarian Cancer:
More than 22,000 women in the United States are newly-diagnosed with ovarian cancer each year. Approximately 80% of all women with ovarian cancer have their disease recur, and 20-30% of recurrences occur within 6 months of the end of first-line therapy. The majority of patients with ovarian cancer (more than 70%), present with advanced disease at initial diagnosis, and women with advanced ovarian cancer tend to have multiple relapses and undergo several rounds of chemotherapy. There have been modest gains in ovarian cancer statistics in the last two decades, with only a small percentage of improvement in overall survival rates for recurrent ovarian cancer.
About Precision Therapeutics:
Precision Therapeutics, Inc., a life-science company located in Pittsburgh, PA, is dedicated to personalizing cancer care and improving patient outcomes. As leaders in the science of individualizing cancer therapy, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual’s cancer. In addition to ChemoFx, Precision also offers BioSpeciFx®, a portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis. For more information, visit: www.precisiontherapeutics.com or www.chemofx.com.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
Jul. 28, 2016 07:15 PM EDT Reads: 343
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Jul. 28, 2016 07:15 PM EDT Reads: 1,225
"We view the cloud not really as a specific technology but as a way of doing business and that way of doing business is transforming the way software, infrastructure and services are being delivered to business," explained Matthew Rosen, CEO and Director at Fusion, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 28, 2016 06:45 PM EDT Reads: 1,627
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Jul. 28, 2016 06:30 PM EDT Reads: 1,655
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Jul. 28, 2016 06:00 PM EDT Reads: 949
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
Jul. 28, 2016 05:30 PM EDT Reads: 1,858
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 28, 2016 05:30 PM EDT Reads: 2,213
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
Jul. 28, 2016 05:00 PM EDT Reads: 426
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Jul. 28, 2016 04:30 PM EDT Reads: 1,186
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Jul. 28, 2016 04:30 PM EDT Reads: 904
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
Jul. 28, 2016 04:15 PM EDT Reads: 369
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Jul. 28, 2016 04:15 PM EDT Reads: 1,773
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Jul. 28, 2016 03:45 PM EDT Reads: 1,027
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
Jul. 28, 2016 03:45 PM EDT Reads: 1,120
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Jul. 28, 2016 03:30 PM EDT Reads: 381